Lake Street has initiated coverage on AngioDynamics (ANGO, Financial), assigning a Buy rating and setting a price target of $24. The firm highlights the company's strategic shift towards developing higher-growth and higher-margin products in cardiovascular and cancer treatment spheres. This transformation positions AngioDynamics for a valuation more aligned with premium medical technology firms, which could elevate its stock value. According to an analyst's note, the market has not fully recognized the company's recent strategic realignment, suggesting a potential revaluation is due.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for AngioDynamics Inc (ANGO, Financial) is $15.67 with a high estimate of $16.00 and a low estimate of $15.00. The average target implies an upside of 81.12% from the current price of $8.65. More detailed estimate data can be found on the AngioDynamics Inc (ANGO) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, AngioDynamics Inc's (ANGO, Financial) average brokerage recommendation is currently 1.7, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for AngioDynamics Inc (ANGO, Financial) in one year is $8.26, suggesting a downside of 4.51% from the current price of $8.65. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the AngioDynamics Inc (ANGO) Summary page.
ANGO Key Business Developments
Release Date: July 15, 2025
- Total Revenue: $80.2 million, representing growth of over 12% year-over-year.
- Med Tech Revenue: $35.8 million, a 22% increase.
- Med Device Revenue: $44.4 million, an increase of 6.2%.
- Gross Margin: 52.7%, with a 204 basis point negative impact from tariffs.
- Adjusted EBITDA: $3.4 million, compared to $1.5 million in the previous year.
- Free Cash Flow: Over $15 million generated in the quarter.
- Adjusted Net Loss: $1.1 million, or an adjusted loss per share of $0.03.
- Cash and Cash Equivalents: $55.9 million as of May 31, 2025.
- Auryon Revenue: $15.6 million, growing 19.7% year-over-year.
- Mechanical Thrombectomy Revenue: Increased 44.7% year-over-year.
- AngioVac Revenue: $8.2 million, a 39.5% year-over-year increase.
- AlphaVac Revenue: $3.1 million, a 60.8% year-over-year increase.
- NanoKnife Revenue: $7.2 million, a decrease of 2.5%.
- Tariff Expense: $1.6 million incurred in the fourth quarter.
- Fiscal Year 2026 Revenue Guidance: $305 million to $310 million, representing growth of 4% to 6%.
- Fiscal Year 2026 Gross Margin Guidance: 53.5% to 55.5%, inclusive of estimated tariff impact.
- Fiscal Year 2026 Adjusted EBITDA Guidance: $3 million to $8 million, inclusive of estimated tariff impact.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- AngioDynamics Inc (ANGO, Financial) reported a strong fourth quarter with total revenue of $80.2 million, representing a growth of over 12% year-over-year.
- The Med Tech segment showed impressive growth, with a 22% increase in revenue, driven by products like Auryon and mechanical thrombectomy devices.
- The Auryon platform has achieved 16 consecutive quarters of double-digit growth, highlighting its strong market position and adoption.
- The company has successfully expanded its international market presence, particularly in Europe, following the CE mark approval for Auryon.
- AngioDynamics Inc (ANGO) has made significant progress in clinical trials and regulatory approvals, positioning products like NanoKnife for future growth with new reimbursement codes effective in 2026.
Negative Points
- The company faced a $1.6 million impact from tariffs in the fourth quarter, affecting gross margins and profitability.
- Despite growth in the Med Tech segment, the NanoKnife revenue saw a decrease of 2.5% due to a decline in capital sales.
- The company anticipates a continued impact from tariffs in fiscal year 2026, with an estimated cost of $4 million to $6 million.
- There is uncertainty regarding the regulatory pathway for the blood return feature of the AlphaVac product, which could impact its market adoption.
- The Med Device segment showed minimal growth, with only a 0.8% increase in revenue for the fiscal year 2025.
